Surmodics Management
Management criteria checks 3/4
Surmodics' CEO is Gary Maharaj, appointed in Dec 2010, has a tenure of 13.42 years. total yearly compensation is $3.53M, comprised of 18.2% salary and 81.8% bonuses, including company stock and options. directly owns 1.35% of the company’s shares, worth $4.92M. The average tenure of the management team and the board of directors is 6 years and 13.4 years respectively.
Key information
Gary Maharaj
Chief executive officer
US$3.5m
Total compensation
| CEO salary percentage | 18.2% |
| CEO tenure | 13.4yrs |
| CEO ownership | 1.3% |
| Management average tenure | 6yrs |
| Board average tenure | 13.4yrs |
Recent management updates
Recent updates
We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17
News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts
Jun 26An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued
Jun 22Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher
Apr 17Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package
Feb 03Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Surmodics gets additional $125M in credit facility
Oct 17Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M
Jul 27Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)
Jul 22Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 03Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why
Feb 04Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?
Dec 24Estimating The Fair Value Of Surmodics, Inc. (NASDAQ:SRDX)
Aug 13When Should You Buy Surmodics, Inc. (NASDAQ:SRDX)?
Jun 09Is Now The Time To Put Surmodics (NASDAQ:SRDX) On Your Watchlist?
May 10Surmodics EPS misses by $0.01, beats on revenue
Apr 28How Much Are Surmodics, Inc. (NASDAQ:SRDX) Insiders Taking Off The Table?
Feb 05
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$14m |
| Dec 31 2023 | n/a | n/a | US$6m |
| Sep 30 2023 | US$4m | US$640k | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$36m |
| Dec 31 2022 | n/a | n/a | -US$32m |
| Sep 30 2022 | US$3m | US$620k | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | n/a | n/a | US$2m |
| Sep 30 2021 | US$3m | US$602k | US$4m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | US$7m |
| Dec 31 2020 | n/a | n/a | US$701k |
| Sep 30 2020 | US$3m | US$585k | US$1m |
| Jun 30 2020 | n/a | n/a | US$8m |
| Mar 31 2020 | n/a | n/a | US$7m |
| Dec 31 2019 | n/a | n/a | US$6m |
| Sep 30 2019 | US$2m | US$568k | US$8m |
| Jun 30 2019 | n/a | n/a | US$2m |
| Mar 31 2019 | n/a | n/a | -US$2m |
| Dec 31 2018 | n/a | n/a | -US$2m |
| Sep 30 2018 | US$2m | US$551k | -US$4m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | n/a | n/a | US$1m |
| Dec 31 2017 | n/a | n/a | US$70k |
| Sep 30 2017 | US$2m | US$526k | US$4m |
Compensation vs Market: Gary's total compensation ($USD3.53M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
CEO
Gary Maharaj (60 yo)
13.4yrs
Tenure
US$3,527,263
Compensation
Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$3.53m | 1.35% $ 4.9m | |
| Senior VP of Finance & Information Technology and CFO | 6yrs | US$1.30m | 0.53% $ 1.9m | |
| Senior VP of Legal | 4yrs | US$1.10m | 0.15% $ 566.8k | |
| Senior VP & President of Medical Device Coatings | 19.6yrs | US$1.12m | 0.37% $ 1.4m | |
| Senior VP & President of Vascular Interventions | 2yrs | US$1.49m | 0.26% $ 932.7k | |
| Corporate Controller | 6yrs | no data | 0.058% $ 213.7k | |
| Senior VP of Human Resources & President of In Vitro Diagnostics | 4.1yrs | US$970.92k | 0.43% $ 1.6m |
6.0yrs
Average Tenure
58yo
Average Age
Experienced Management: SRDX's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$3.53m | 1.35% $ 4.9m | |
| Independent Director | 10.3yrs | US$186.50k | 0.066% $ 242.4k | |
| Independent Director | 13.3yrs | US$185.00k | 0.056% $ 203.9k | |
| Independent Non-Executive Chair of the Board | 16.3yrs | US$229.00k | 0.13% $ 458.9k | |
| Independent Director | 22.3yrs | US$176.50k | 0.033% $ 122.2k | |
| Independent Director | 7.1yrs | US$176.50k | 0.024% $ 86.1k |
13.4yrs
Average Tenure
68yo
Average Age
Experienced Board: SRDX's board of directors are seasoned and experienced ( 13.4 years average tenure).